Biocept, Inc. BIOC
We took notice of BIOC on our routine morning scan today as a possible bottom play, as the stock tumbled to 8-month lows on Friday. At the same time, the company released a PR this morning pertaining to the signing of a potentially lucrative, worldwide distribution agreement, a snippet of which we’ve included below.
We think it makes for an interesting confluence of events, and that’s why we’re going to be tracking BIOC closely as we kick off a fresh trading week.
SAN DIEGO, Aug. 14, 2017 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has signed an exclusive global Distribution Agreement excluding China, for the Company’s proprietary blood collection tubes (BCTs) with VWR International, LLC (>>View Full PR)
National and International Events Affecting Markets
There was a fair bit of hysteria going out over the newsreels last week over a potential nuclear conflict between North Korea and the US, and it led to a tough week for stocks in general. Whether this week plays out as a bear or a bull remains to be seen, but we’ll want to have options ideas lined up for either eventuality.
This morning, we’ve seen some signs of an abatement of those fears as stocks around the globe have perked up, and in the event that a rebound for domestic stocks is also in the cards for this week, we’ll want to signal the range of SPDR S&P 500 ETF Trust (SPY) Weekly $244.50-246 Calls for observation.
However if other outside factors, such as the civil unrest and domestic terrorism that unfolded in Virginia over the weekend serves to hurt US markets further, we may find ourselves more interested in tracking the iPath S&P 500 VIX ST Futures ETN (VXX) Weekly $12 and 12.50 Calls.
Extended Watchlist:
ZSAN, FCAU, CLMT,CVM CERC, FRSX